{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cacciottolo PJ"],"funding":["JP Moulton Charitable Foundation","National Institute for Health Research (NIHR)"],"pagination":["e037457"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8051397"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(4)"],"pubmed_abstract":["<h4>Introduction</h4>Elevated low-density lipoprotein cholesterol (LDL-C) is a strong independent risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only evidence-based approach to reduce CV morbidity and mortality. Secondary prevention statin trials in combination with ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors showed that there is no 'J shaped curve' in LDL-C levels with regard to CV outcomes. The lowest threshold beyond which reduction of LDL-C confers no further CV benefits has not been identified.The INTENSITY-HIGH study seeks to explore physiological mechanisms mediating CV benefits of LDL-C lowering by PCSK9 inhibition in patients with established cardiovascular disease (CVD). The study examines the change"],"journal":["BMJ open"],"pubmed_title":["Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study."],"pmcid":["PMC8051397"],"funding_grant_id":["NF-SI-0515-10093"],"pubmed_authors":["Kostapanos MS","McEniery CM","Vamvaka E","Cacciottolo PJ","Hernan Sancho E","Pavey H","Kaloyirou F","Helmy J","Wilkinson IB","Hubsch A","Cheriyan J"],"additional_accession":[]},"is_claimable":false,"name":"Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.","description":"<h4>Introduction</h4>Elevated low-density lipoprotein cholesterol (LDL-C) is a strong independent risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only evidence-based approach to reduce CV morbidity and mortality. Secondary prevention statin trials in combination with ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors showed that there is no 'J shaped curve' in LDL-C levels with regard to CV outcomes. The lowest threshold beyond which reduction of LDL-C confers no further CV benefits has not been identified.The INTENSITY-HIGH study seeks to explore physiological mechanisms mediating CV benefits of LDL-C lowering by PCSK9 inhibition in patients with established cardiovascular disease (CVD). The study examines the change","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-04-18T05:28:22.643Z","creation":"2022-02-09T16:06:47.578Z"},"accession":"S-EPMC8051397","cross_references":{"pubmed":["33849844"],"doi":["10.1136/bmjopen-2020-037457"]}}